Results 131 to 140 of about 2,570 (187)

Does Amyotrophic Lateral Sclerosis (ALS) Have Metabolic Causes from Human Evolution? [PDF]

Cells
Spedding M.
europepmc   +1 more source

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers. [PDF]

Mov Disord
Agin-Liebes J, Haimovich A, Griep R, Hatcher NG, Yao L, Waters C, Padmanabhan S, Alcalay RN.   +7 more
europepmc   +1 more source

Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypes. [PDF]

Orphanet J Rare Dis
Kilavuz S, Wallom KL, Caçote ACGAA, Donald A, D'Amore S, Page K, Tan CY, Te Vruchte D, Sturchio A, Tsitsi P, Hertz E, Andréasson M, Markaki I, Svenningsson P, Cox TM, Platt FM, MRC GAUCHERITE Consortium.   +16 more
europepmc   +1 more source

GBA1 Variants with Unknown Classification Are Modest Contributors to Parkinson's Disease Susceptibility. [PDF]

Mov Disord
Parlar SC, Lee Y, Gan-Or Z.
europepmc   +1 more source

Exploring delayed diagnosis in Gaucher disease: insights from a community survey and potential solutions. [PDF]

Orphanet J Rare Dis
Aragón DPP, Collin-Histed T, Abdelwahab M, Espinosa JV, Chertkoff R, Balzekiene A, Pacey J.   +6 more
europepmc   +1 more source

Establishment of an N-Glycan Profiling Method for Three ERT Enzymes Used in Gaucher Disease Therapy. [PDF]

Molecules
Chen J, Hu X, Wang L, Xu K, Li J, Wang Y, Liang C.   +6 more
europepmc   +1 more source

Lipid accumulation drives cellular senescence in dopaminergic neurons. [PDF]

Aging (Albany NY)
Russo T, Riessland M.
europepmc   +1 more source

Development of a Lentiviral Vector for High-Yield Production of Synthetic and Recombinant GCase for Gaucher Disease Therapy. [PDF]

Int J Mol Sci
Coelho AC, Wiezel CEV, de Campos AC, Figueiredo LLS, Suardi GAM, de Paula Bernardes J, da Cunha Tirapelli DP, Faça VM, Abraham KJ, Carlotti-Júnior CG, Siciliano V, Weiss R, Gerson S, Fontes AM.   +13 more
europepmc   +1 more source

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease. [PDF]

J Neurol
Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N, Duffen J, Wyse RK, Stott SRW, Matthews H, Dexter D, Ikeji F, Moss J, Watts P, Foltynie T, Kieburtz K, Rascol O, Poewe W, Schapira AHV.   +18 more
europepmc   +1 more source

Underlying Mechanisms of GBA1 in Parkinson's Disease and Dementia with Lewy Bodies: Narrative Review. [PDF]

Genes (Basel)
Bougea A.
europepmc   +1 more source